Research Desk Line-up: Lakeland Industries Post Earnings Coverage

LONDON, UK / ACCESSWIRE / June 22, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for leading global medical technology firm, Becton, Dickinson and Co. (NYSE: BDX) ("BD"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=BDX. The Company announced on June 20, 2017, that a new line of Snowden-Pencer 3.00 mm laparoscopic ergonomic take-apart instruments received US FDA 510(k) clearance for use in laparoscopic surgery. The new Snowden-Pencer is a micro-laparoscopic instrument used in procedures to provide patients with a virtually scar-less procedure while reducing post-operative pain and improving post-operative appearance. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Medical Instruments & Supplies industry. Pro-TD has currently selected Lakeland Industries, Inc. (NASDAQ: LAKE) for due-diligence and potential coverage as the Company announced on June 14, 2017, its financial results for Q1 FY18 which ended on April 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Lakeland Industries when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on BDX; also brushing on LAKE. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=BDX

http://protraderdaily.com/optin/?symbol=LAKE

The Announcement

According to the Company, the new Snowden-Pencer 3.0 mm laparoscopic ergonomic take-apart instruments are designed for micro-laparoscopic surgery, and work in a fashion similar to 5.0 mm instruments. The jaw lengths of the devices are similar to those of standard laparoscopic instruments, delivering surgeons with a less invasive approach, without compromising instrument functionality.

This particular launch of the new line enables BD to deliver one of the most customizable portfolios of 3.0 mm micro-laparoscopic instruments available. The product line offers 26 different jaw patterns, 2 different lengths (24 cm, 36 cm), and 6-take-apart handles, resulting in 312 combinations to target procedures in different specialties. The devices are also compatible with an interchangeable modular system that includes the standard Snowden-Pencer 5.0 mm and 10.0 mm laparoscopic instruments.

According to BD, minimally invasive micro-laparoscopic surgery is a steadily growing segment, resulting from patient demand for less invasive surgical options and scar reduction. The innovative new line of instruments enables the providers to deliver best surgical options for their patients.

BD is a leading medical technology firm that excels in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The Company offers innovative solutions that help advance medical research and genomics, while enhancing the diagnosis of infectious disease and cancer, hence, improving medication management, promoting infection prevention, and equipping surgical and interventional procedure, to support the management of diabetes.

BD Growth Prospects

BD currently partners with leading organizations across the world to address some of the most challenging global health issues. The Company has about 50,000 associates across 50 countries which work in close collaboration with clients and partners to enhance outcomes, lower health delivery costs, and increase efficiencies of surgical procedures.

The Company recently acquired C.R. Bard, Inc., a medical technology leader in the segments of vascular, oncology, and surgical specialty products, on April 23, 2017. Under the terms of the agreement, BD acquired Bard for $317.00 per Bard's common share in cash and stock for a total purchase price of $24 billion. This transaction was immediately accretive and expected to generate high-single digit accretion to the Company's adjusted EPS in FY19. The transaction is expected to improve BD's gross margins by about 300 basis points in FY18 and generate a strong cash flow.

Prior to the announcement, on April 04, 2017, the Company announced the acquisition of Israel-based Caesarea Medical Electronics ("CME"). The acquisition of CME enabled the Company to expand its infusion portfolio to include ambulatory, home, and specialty acute care infection firms. The integration enabled BD to strengthen its strategy to execute medication management across the health care continuum. The additional details of the transaction were not disclosed under the announcement.

Last Close Stock Review

On Wednesday, June 21, 2017, the stock closed the trading session at $193.49, slightly down 0.50% from its previous closing price of $194.46. A total volume of 1.58 million shares have exchanged hands. Becton, Dickinson's stock price surged 5.94% in the last three months, 16.04% in the past six months, and 13.80% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 16.88%. The stock is trading at a PE ratio of 32.06 and has a dividend yield of 1.51%. At Wednesday's closing price, the stock's net capitalization stands at $43.87 billion.

--

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily